Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma • Poster presented today at CTOS 2026 expands on the survival data first reported in the abstract (announced 11 November 2026), which showed a 12-month disease-free survival (DFS) of 81.1% in...
Encouraging Disease-Free Survival in Phase II Sarcoma Trial
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Higher levels of tumor-infiltrating lymphocytes and treatment-related hyalinisation were associated with improved survival outcomes. The findings support the potential of efti-based combination therapy and indicate a strong rationale for further clinical evaluation.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Immutep
- Immutep Investor Update
- Immutep Announces Release of CTOS 2026 Abstract Reporting First Survival Data from EFTISARC-NEO
- Immutep Expands US Patents for Efti Combination Therapies
- EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract
- IMP761 Late-Breaking Abstract at ACR Convergence 2026 Highlights Statistically Significant & Exposure-Dependent Inhibition of T-Cell-Driven Immune Responses
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep